Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenström's Macroglobulinemia
- 1 February 2011
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 11 (1), 152-156
- https://doi.org/10.3816/clml.2011.n.036
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Histone deacetylase inhibitors and genomic instabilityCancer Letters, 2009
- Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemiaBlood, 2009
- Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's MacroglobulinemiaJournal of Clinical Oncology, 2009
- From the bench to the bedside: emerging new treatments in multiple myelomaBest Practice & Research Clinical Haematology, 2007
- Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphomaEuropean Journal of Haematology, 2007
- Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu miceExperimental Hematology, 2007
- Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007
- The Treatment of Relapsed and Refractory Multiple MyelomaHematology, 2007
- Diagnosis and Management of Waldenstrom's MacroglobulinemiaJournal of Clinical Oncology, 2005
- Modified Randomization Tests for Nonparametric HypothesesThe Annals of Mathematical Statistics, 1957